- Conditions
- Inflammation, Pain
- Interventions
- Vehicle of Loteprednol Etabonate, Loteprednol Etabonate
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 25
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chalazion, Hordeolum
- Interventions
- loteprednol etabonate/tobramycin opthalmic suspension, vehicle
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- Up to 6 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Erie, Pennsylvania
- Conditions
- Ocular Inflammation
- Interventions
- Loteprednol Etabonate, Vehicle of Ophthalmic Loteprednol Etabonate
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- High Point, North Carolina
- Conditions
- Pseudophakia, Inflammation
- Interventions
- loteprednol 0.5% ophthalmic solution
- Drug
- Lead sponsor
- Toyos Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Independence, Missouri
- Conditions
- Ocular Inflammation
- Interventions
- 0.5% Loteprednol Etabonate Ophthalmic Ointment, Vehicle of Loteprednol Etabonate Ophthalmic Ointment
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Dry Eye
- Interventions
- Dexamethasone
- Drug
- Lead sponsor
- Research Insight LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 3
- States / cities
- Hemet, California • Laguna Hills, California • St Louis, Missouri
- Conditions
- Dry Eye Disease, Keratoconjunctivitis Sicca
- Interventions
- Lotemax, Restasis
- Drug
- Lead sponsor
- Ophthalmic Consultants of Long Island
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Lynbrook, New York
- Conditions
- Conjunctivitis
- Interventions
- loteprednol etabonate and tobramycin, loteprednol etabonate, Tobramycin, Vehicle of Zylet
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 1 Week to 6 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Erie, Pennsylvania
- Conditions
- Cataract
- Interventions
- Loteprednol etabonate, Prednisolones acetate
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- Up to 11 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Inflammation, Pain
- Interventions
- Loteprednol etabonate, Vehicle of Loteprednol Etabonate
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Intraocular Inflammation
- Interventions
- Not listed
- Lead sponsor
- Associated Eye Care, Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Edgewood, Kentucky • Stillwater, Minnesota
- Conditions
- Blepharokeratoconjunctivitis
- Interventions
- Loteprednol etabonate and tobramycin ophthalmic suspension, Tobramycin and dexamethasone ophthalmic suspension
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- High Point, North Carolina
- Conditions
- Corneal Endothelial Dystrophy, Corneal Edema
- Interventions
- loteprednol etabonate 0.25% ophthalmic suspension
- Drug
- Lead sponsor
- Price Vision Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Sjogren's Disease
- Interventions
- Administration of Lotemax
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 50 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Bilateral Conjunctivitis (Disorder)
- Interventions
- Dexamethasone ophthalmic insert 0.4Mg, 0.2% loteprednol etabonate ophthalmic suspension, olopatadine hydrochloride ophthalmic solution 0.7%
- Drug
- Lead sponsor
- Clinical Research Center of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Pompano Beach, Florida
- Conditions
- Dry Eye
- Interventions
- Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free
- Drug
- Lead sponsor
- Research Insight LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Hemet, California • Laguna Hills, California • Brecksville, Ohio
- Conditions
- Dry Eye
- Interventions
- Cyclosporine, Loteprednol Etabonate, Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert
- Drug
- Lead sponsor
- Thomas Chester, OD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Brecksville, Ohio
- Conditions
- Dry Eye
- Interventions
- loteprednol etabonate ophthalmic suspension, 0.5%, vehicle of loteprednol etabonate
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Cataract, Pain, Ocular Inflammation
- Interventions
- Loteprednol Etabonate Ophthalmic Gel dosed TID, Loteprednol Etabonate Ophthalmic Gel dosed BID, Vehicle Gel
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Oceanside, California • Miami, Florida + 3 more
- Conditions
- Dry Eye Disease
- Interventions
- Loteprednol etabonate, Artificial Tears, Restasis
- Drug
- Lead sponsor
- Edward Holland, MD
- Other
- Eligibility
- 21 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Edgewood, Kentucky
- Conditions
- Inflammation, Pain, Cataract
- Interventions
- Loteprednol Etabonate Gel (BID), Vehicle Gel (BID)
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Inflammation, Pain, Cataract
- Interventions
- Loteprednol Etabonate Gel (BID), Loteprednol Etabonate Gel (TID), Vehicle (BID), Vehicle (TID)
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Loteprednol Etabonate Ophthalmic Gel [Lotemax], Refresh Lubricant Eye Drops [Artificial Tears]
- Drug · Other
- Lead sponsor
- Virginia Polytechnic Institute and State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Roanoke, Virginia
- Conditions
- Meibomian Gland Dysfunction, Posterior Blepharitis
- Interventions
- Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts